MRC Holland is looking for DNA samples for the development and quality control of our many products. Read more.
The upcoming NXtec-MS™ DM025 Developmental Disorders brings key targets together in a single assay, combining copy number and methylation analysis to provide a more comprehensive view of the genomic alterations associated with developmental disorders. Read more.
The latest addition to MRC Holland’s digitalMLPA portfolio, NXtec™ D038 Carrier Plus, is a comprehensive high-throughput assay for carrier status determination. Read more.
We are pleased to share the results of our collaboration with GeneMind, demonstrating the compatibility of digitalMLPA™ with the GeneMind FASTASeq 300 and SURFSeq 5000 sequencing platforms. Read more.
Important updates for Beckman MLPA users relating to a new version of Coffalyser.Net with improved quality checks and the gradual phasing out of our Cy5-labelled primers. Read more.
A new publication by researchers at MRC Holland highlights the potential of EZtec-MS, a new variation of the digitalMLPA technology, for newborn screening purposes. Read more.
At MRC Holland, we are gradually updating probe location annotations across our product documentation to align with MANE (Matched Annotation from NCBI and EMBL-EBI). Read more.
We have reviewed our pricing structure for 2027 and effective from January 1st, 2027, our list prices will increase by an average of 2.9%, with variations depending on product category. Read more.
We are pleased to announce new distribution partners in Mexico and Egypt, further strengthening access to MRC Holland products for laboratories in these countries. Read more.
MRC Holland and Amsterdam UMC have launched a collaborative project, supported by Health~Holland, and aimed at improving the reliability of patient-derived stem cell models used in personalized medicine. Read more.
Join our mailing list to receive the latest information about our products, technologies and website.